<DOC>
	<DOCNO>NCT01028937</DOCNO>
	<brief_summary>The purpose U.S. Clinical Trial treatment sight eye investigate safety effectiveness optimal keratoplasty ( Opti-K™ ) treatment hyperopia correction use NTK Enterprises ( NTK ) Opti-K System .</brief_summary>
	<brief_title>Hyperopia Correction Using NTK Optimal Keratoplasty ( Opti-K ) System</brief_title>
	<detailed_description />
	<mesh_term>Hyperopia</mesh_term>
	<criteria>Enrollment limited subject satisfy follow inclusion criterion : Male Female Any race Patient least 40 year old . Patient bilateral sight least one eye low hyperopia [ +1.0 +2.75 D spherical component manifest refraction , less equal 0.75 D cylindrical component manifest refraction ( minus cylinder format ) manifest refraction , spherical equivalent +1.0 +2.5 D ] . Patient document stable refraction define change baseline MRSE ≤ 0.5 D 12 month period prior primary OptiK Tx verify consecutive refraction , medical record prescription history . Patient able tolerate full cycloplegic refraction cycloplegia . Patient distance uncorrected visual acuity ( DUCVA ) less 20/40 good equal 20/80 eye . Patient stable DUCVA document change ≤ 1 line DUCVA 12 month period prior baseline measurement . Patient distance near best spectacle correct visual acuity ( DBSCVA NBSCVA ) 20/40 good eye . Patient normal videokeratography ( i.e. , without distort unclear corneal mire ) . Contacts lens wearer must : 1. discontinue use soft gas permeable contact lenses least two week prior baseline measurement discontinue use hard rigid gas permeable contact lens least three week prior baseline measurement 2. two central keratometry reading two manifest refraction take least one week apart differ 0.5 D either meridian ; mire regular . Patient willing able comply pretreatment followup requirement , include ability read English complete NEIRQL questionnaire . Patient understand nature procedure , well potential\ risk limitation treatment , provide informed consent Patients permit enroll study meet follow exclusion criterion : Patients latent hyperopia &gt; 1.0 D ( i.e. , baseline MRSE CRSE differ 1.0 D ) Patients nystagmus Patients previous intraocular corneal surgery Patients residual , recurrent active ocular disease corneal abnormality , include follow : corneal diameter &lt; 9 mm ; central corneal thickness &lt; 500 µm ; mild severe dry eye disease ; uncontrolled uveitis ; severe blepharitis ; lagophthalmos ; glaucoma ; intraocular pressure &gt; 21 mm Hg ; cataract ; history uveitis ; corneal shape disorder ( keratoconus , keratoglobus , pellucid marginal degeneration , significant irregular corneal astigmatism , etc . ) ; history herpes zoster/simplex keratitis Patients cloudy cornea cloudy anterior chamber Patients allergy anesthetic postoperative medication Patients chronic allergic reaction , tear and/or ocular irritation Patients hypersensitive pain stimulus Patients take systemic medication ( NSAIDs , etc . ) affect wound heal Patients take amiodarone , isotretinoin and/or sumatriptan Patients require administration topical systemic ophthalmic medication study medication use corticosteroid antimetabolite specifically contraindicate . Patients recent history ( within one week prior treatment ) use ophthalmic medication contain preservative ( benzalkonium chloride , etc . ) and/or ocular drug cytotoxic Patients immunocompromised ( , example , infectious disease HIV , herpes , etc . and/or immunosuppressive medication ) autoimmune disease lupus , rheumatoid arthritis , etc . Patients diabetes Pregnant , plan pregnant lactate woman Patients unusual hormonal status due , example , hormone replacement therapy Patients take plan take oral contraceptive within one year prior , follow , treatment Patients unrealistic expectation Patients participate ophthalmic clinical trial clinical investigation Persons , determination investigator , competent understand procedure action ask research subject Persons may able complete requirement return investigator 's clinic period study , may difficult locate contact short notice . This preclude vacation travel . Persons achieve corneal applanation use SAWSR device tolerate application SAWSR device remain motionless least 5 second verify proper SAWSR mounting . Patients likely expose high level ultraviolet radiation ( sunlight , tan light , etc . ) without protective eyewear one year period follow OptiK treatment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hyperopia correction</keyword>
	<keyword>Laser vision correction</keyword>
	<keyword>Optimal keratoplasty</keyword>
</DOC>